Antimicrobial activities of peptide Cbf-K16 against drug-resistant Helicobacter pylori infection in vitro and in vivo

This study further evaluated the therapeutic potential and the mode of action underlying Cbf-K16 against clarithromycin- and amoxicillin-resistant H. pylori SS1. The MIC and MBC of Cbf-K16 against the tested H. pylori were 16 and 32 μg/ml, respectively, and its killing kinetics was time-dependent, reflecting the thorough elimination of drug-resistant bacteria within 24 h. This peptide also protected H. pylori-infected gastric epithelial cells (GES-1) from death by reducing the cell supernatant and intracellular bacterial counts by 1.9 and 2.9-log10 units, respectively. These data indicated the powerful antimicrobial effects of Cbf-K16 in vitro. Meanwhile, notable antimicrobial activity in the mouse gastritis model was observed, with decreasing bacterial counts by 3.9-log10 units in stomach tissues and Cbf-K16 could effectively suppress the secretion of inflammatory cytokine IL-8. For its mode of action, Cbf-K16 not only neutralized the negative potential and increased the membrane uptake of NPN and PI by 78.5% and 85.1%, respectively, but also bound to genomic DNA, which in turn downregulated the expression of adhesion genes (alpA and alpB) and virulence gene (cagA), indicating its effective activities on membrane disruption, DNA-binding and gene expression. The data above demonstrated that Cbf-K16 possessed effective antimicrobial and anti-inflammatory activities and downregulated the expression of adhesion- and cytotoxin-associated genes of drug-resistant H. pylori S...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research

Related Links:

ConclusionDiabetes, HCV and NAFLD predispose to refractory H. Pylori which need culture and sensitivity testing.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Conclusion: Our present study indicated, for the first time, that ABS could act against H. pylori. ABS is clinically used for the management of GI bleeding due to benign and malignant GI lesions. Thus, the possible anti-H. pylori effect of ABS shall expand the therapeutic spectrum of the drug in GI lesions in relation to H. pylori infection such as peptic ulser disease (PUD) and lymphoid tissue (MALT) lymphomagenesis. PMID: 30761849 [PubMed - in process]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
ConclusionsA diversity of point mutations in the 23S rRNA domain V was observed in clinical H. pylori isolates. The rate of phenotypically CLR-resistant H. pylori is significantly increasing in central Vietnam. Further research is necessary to clarify the role of the combination of 23S rRNA domain V mutations in the molecular mechanism of CLR resistance.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
ConclusionsThere was a diversity of point mutations of 23S rRNA domain V of clinical strains of H. pylori. The rate of phenotypic CLA-resistant H. pylori is remarkably increasing in central Vietnam. Further research is necessary to clarify the role of the combination of 23S rRNA domain V mutations in the molecular mechanism of clarithromycin-resistance.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Publication date: September 2018Source: Journal of Global Antimicrobial Resistance, Volume 14Author(s): Amin Talebi Bezmin Abadi, Yoshio YamaokaAbstractHelicobacter pylori induces chronic gastritis and duodenal ulcer in a small fraction of the colonised population. Three decades after the discovery of H. pylori and disclosure of an urgent need for eliminating the bacterium in patients, it seems that we are still in the first steps of dealing with this mysterious organism. Treatment of H. pylori is a complex dilemma for clinicians, a repeating sentence by many scientists who spend years on this research topic. Apart from ma...
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Authors: Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E Abstract INTRODUCTION: Helicobacter pylori is a Gram-negative bacterium that causes chronic gastritis, dyspepsia, peptic ulcers and gastric cancer. Over half the world's population is infected with H. pylori, with higher prevalence in developing countries. Areas covered: In this review, current guidelines on H. pylori therapy, such as the Toronto consensus statement, the Maastricht V/Florence consensus report and the American College of Gastroenterology guidelines are compared. Also, we anal...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Publication date: Available online 23 March 2018 Source:Journal of Global Antimicrobial Resistance Author(s): Amin Talebi Bezmin Abadi, Yoshio Yamaoka Helicobacter pylori (H. pylori) infection induces chronic gastritis and duodenal ulcer in small fraction of infected population. Three decades after introduction of the H. pylori and disclosure of urgent need for eliminating the bacterium in patients, it seems that we are still in first steps of dealing with this mysterious organism. H. pylori treatment is a complex dilemma for clinicians, a repeating sentence by many of scientists whom spend years on this research topic. A...
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Authors: Mandalari G, Bisignano C, Cirmi S, Navarra M Abstract It is known that Helicobacter pylori infection is associated with chronic gastritis, peptic ulcer, and gastric carcinoma. Due to the increased side effects of the treatment regimens and the development of antimicrobial resistance, a number of natural compounds have been tested as potential alternatives. In this review, we will examine the current knowledge on the effect of Citrus fruits and their derivatives against H. pylori, highlighting the remaining outstanding questions on the development of novel therapeutic strategies. PMID: 28408943 [PubMed - in process]
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Conclusions: The rates of resistance to clarithromycin, metronidazole, and levofloxacin were high in Bangladesh, which suggests that triple therapy based on these drugs may not be useful as first-line therapies in Bangladesh. Alternative strategies such as furazolidone-based triple therapy, bismuth-based quadruple therapies, or sequential therapy may be more effective for patients in in Bangladesh.
Source: The Journal of Infection in Developing Countries - Category: Infectious Diseases Source Type: research
In conclusion, more than two-thirds of the isolated H. pylori strains showed resistance to at least one of the antibiotics for H. pylori treatment. Metronidazole resistance was most prevalent amongst the isolates tested. Emergence of dual and multidrug resistance is of great concern and there is an urgent need for regular antibiotic resistance surveillance studies. Amoxicillin- and clarithromycin-based anti-H. pylori regimens commonly prescribed for triple therapy in India show least resistance and hence are appropriate for anti-H. pylori management in India.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
More News: Amoxicillin | Antimicrobial Resistance | Biaxin | Clarithromycin | Gastritis | Gastroenterology | Genetics | Helicobacter Pylori | Infectious Diseases | Study